health
Multiomic Study Predicts Myeloma Residual-Disease Status After Quadruplet Therapy
An analysis of the MIDAS trial linked molecular features of newly diagnosed multiple myeloma to measurable residual disease after quadruplet induction. A model combining genomic, gene-expression and DNA-methylation data achieved an AUC of 0.77 in a held-out group from the same trial.